Sort
21,453 grants matching “tuberculosis”
Bacterial and host determinants of progression, manifestations and consequences of TB
$391,945Jerrold J. Ellner · Rbhs-New Jersey Medical School · U19 · FY2021 · AI
Testing and Counseling for HIV: A Multi-Site Study
$391,940Carla M Obermeyer · World Health Organization · R01 · FY2009 · HD
Portable Nanostructured Photonic Crystal Device for HIV-1 Viral Load
$391,872Utkan Demirci · Stanford University · R01 · FY2016 · AI
PS05-003, TUBERCULOSIS CONTROL PROGRAM AND AIDS
$391,826Mary J Jones · Iowa State Dept Of Public Health · U52 · FY2008 · PS
TUBERCULOSIS CONTROL PROGRAM AND AIDS
$391,826Mary J Jones · Iowa State Dept Of Public Health · U52 · FY2009 · PS
Discovery of Chemical Probes and Therapeutic Leads, Phase II
$391,800Joseph M Fox · University Of Delaware · P20 · FY2021 · GM
Secretion of Virulence Factors by Mycobacterium tuberculosis
$391,763Jeffery S Cox · University Of California, San Francisco · R01 · FY2006 · AI
ApoVax104-TB as a Novel Vaccine for Tuberculosis
$391,672Kathryn J. Macleod · Apovax, Inc. · R43 · FY2008 · AI
Impact of Diabetes and Hyperlipidemia on Host Defense
$391,510Hardy Kornfeld · Univ Of Massachusetts Med Sch Worcester · R01 · FY2013 · HL
ALVEOLAR MACROPHAGE INNATE IMMUNE FUNCTION IN HIV
$391,500Beth Israel Deaconess Medical Center · R01 · FY2001 · HL
ALVEOLAR MACROPHAGE INNATE IMMUNE FUNCTION IN HIV
$391,500Beth Israel Deaconess Medical Center · R01 · FY2000 · HL
ALVEOLAR MACROPHAGE INNATE IMMUNE FUNCTION IN HIV
$391,500Beth Israel Deaconess Medical Center · R01 · FY2004 · HL
ALVEOLAR MACROPHAGE INNATE IMMUNE FUNCTION IN HIV
$391,500Beth Israel Deaconess Medical Center · R01 · FY2003 · HL
ALVEOLAR MACROPHAGE INNATE IMMUNE FUNCTION IN HIV
$391,500Beth Israel Deaconess Medical Center · R01 · FY2002 · HL
Cell Wall Biogenesis-Target for new Anti-TB drugs
$391,446Colorado State University-Fort Collins · R01 · FY2005 · AI
PHARMACOKINETICS AND TOXICITY OF 2ND LINE ANTI-TB DRUGS IN HIV-INFECTED CHILDREN
$391,328Anneke Catharina Hesseling · Stellenbosch University · R01 · FY2014 · HD
Tuberculosis Pathogenesis and Drug Response
$391,275Christopher M Sassetti · Univ Of Massachusetts Med Sch Worcester · R01 · FY2013 · AI
The Impact of the Cystic Fibrosis infection environment on biofilm development of nontuberculous mycobacteria
$391,237William H. Depas · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · AI
The Impact of the Cystic Fibrosis infection environment on biofilm development of nontuberculous mycobacteria
$391,237William H. Depas · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · AI
Validating cholesterol-mediated Mycobacterium tuberculosis resistance to oxidative stress as a drug target
$391,123Nicole S. Sampson · State University New York Stony Brook · R01 · FY2017 · AI
Design, Syntheses and Studies of Novel Antituberculosis Agents
$391,102Marvin J Miller · University Of Notre Dame · R01 · FY2010 · AI
Statistical Designs and Methods for Double-Sampling for HIV/AIDS
$391,088Constantine E Frangakis · Johns Hopkins University · R01 · FY2015 · AI
Ameliorating systemic gentamicin uptake by sensory hair cells
$390,907Peter S Steyger · Oregon Health & Science University · R01 · FY2013 · DC
Assays and Screens
$390,892Francesca M Marassi · Florida State University · P01 · FY2009 · AI
Treatment of tuberculosis with immunomodulators
$390,890Brigham And Women'S Hospital · R01 · FY2005 · HL